1. Home
  2. CLLS vs PROF Comparison

CLLS vs PROF Comparison

Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$1.04

Market Cap

139.0M

Sector

Health Care

ML Signal

N/A

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

SELL

Current Price

$7.12

Market Cap

248.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CLLS
PROF
Founded
1999
N/A
Country
France
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
248.8M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
CLLS
PROF
Price
$1.04
$7.12
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$5.50
★ $11.14
AVG Volume (30 Days)
84.3K
★ 178.8K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 25.89
EPS
★ N/A
N/A
Revenue
N/A
★ $16,098,000.00
Revenue This Year
N/A
$61.76
Revenue Next Year
N/A
$70.98
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 50.73
52 Week Low
$0.88
$4.91
52 Week High
$5.45
$8.95

Technical Indicators

Market Signals
Indicator
CLLS
PROF
Relative Strength Index (RSI) 40.62 54.23
Support Level $0.94 $6.38
Resistance Level $1.28 $7.19
Average True Range (ATR) 0.11 0.52
MACD 0.03 0.05
Stochastic Oscillator 0.53 54.81

Price Performance

Historical Comparison
CLLS
PROF

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: